Find a Research Study

To find out which of two commonly used IV fluids given in the Emergency Department for sepsis is most effective.

Our purpose is to look at the long-term neurodevelopmental outcomes of preterm neonatal brain abnormalities.

To explore the safety and treatment effect of intravenous (IV) Remodulin as add on therapy in neonates with PPHN compared to placebo.

This is a randomized trial to help determine which of two gold standard treatments, Medication or Cognitive Behavioral Therapy (CBT), or their combination, is most effective when treating anxiety disorders in children and adolescents. Treatment of every child with an anxiety disorder begins with the question of which treatment to start first, and then what to do if that initial treatment is not as helpful as it should be. This study will help patients, families, and clinicians determine which treatment sequences are most helpful for which specific patients.

This is a randomized, double-blind, placebo-controlled study that will evaluate the potential of tildacerfont to reduce GC burden in adult subjects with classic CAH who have LLD ≤ A4 ≤ 2.5x ULN and are on supraphysiologic doses of GC therapy (≥30 mg/day and ≤60 mg/day HCe). This will be the first study of tildacerfont to evaluate GC dose reduction. In addition, this study will characterize clinical outcomes after up to 76 weeks of treatment with tildacerfont. An optional Open-Label Extension Period will provide an open-label treatment with tildacerfont at 200 mg QD for up to 240 weeks.

Study early development in infants who have an older sibling with autism.

Understand the experiences of patients and parents in treatment decision making for children with Neuromuscular Scoliosis (NMS).

To better understand the effects of nutrition in early pregnancy on infant growth and development.

Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.

The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.